Kenvue Inc. (KVUE)
NYSE: KVUE · Real-Time Price · USD
19.28
+0.38 (2.01%)
At close: Jul 24, 2026, 4:00 PM EDT
18.90
-0.38 (-1.97%)
After-hours: Jul 24, 2026, 7:54 PM EDT
Kenvue Employees
Kenvue had 22,000 employees as of December 28, 2025. The number of employees did not change compared to the previous year.
Employees
22,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$695,091
Profits / Employee
$73,727
Market Cap
37.02B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 28, 2025 | 22,000 | 0 | - |
| Dec 29, 2024 | 22,000 | 0 | - |
| Dec 31, 2023 | 22,000 | -200 | -0.90% |
| Dec 31, 2022 | 22,200 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| The Procter & Gamble Company | 109,000 |
| Unilever | 96,092 |
| The Estée Lauder Companies | 57,000 |
| Kimberly-Clark | 36,000 |
| Colgate-Palmolive Company | 33,600 |
| Newell Brands | 21,900 |
| Coty Inc. | 11,636 |
| The Clorox Company | 7,600 |
KVUE News
- 8 hours ago - Kenvue confirms FDA approves Tylenol with Naproxen OTC combination - TheFly
- 10 hours ago - US FDA approves over-the-counter Tylenol combination pill for pain relief - Reuters
- 1 day ago - Kenvue to Announce Second Quarter 2026 Results on August 6, 2026 - Business Wire
- 3 days ago - Kenvue price target raised to $19 from $18 at Barclays - TheFly
- 8 days ago - Kenvue price target raised to $20 from $18 at UBS - TheFly
- 11 days ago - Appeals court revives autism suits against Kenvue’s Tylenol, Bloomberg says - TheFly
- 11 days ago - Appeals court rules Kenvue must face Tylenol autism claims, Bloomberg says - TheFly
- 11 days ago - US appeals court revives private lawsuits linking Tylenol to autism, ADHD - Reuters